During the pre-2022 period, OPDIVO, engineered through collaborative innovation between Ono Pharmaceutical and Bristol Myers Squibb, confronted unprecedented competitive adversity within Japan's rapidly transforming oncology sector. The therapeutic agent witnessed substantial market contraction as KEYTRUDA vs OPDIVO competition reached critical thresholds, with healthcare practitioners...